Cuba, first country to resume face-to-face teaching with all students vaccinated

Cuba, first country to resume face-to-face teaching with all students vaccinated

Health & Medicine

By Mercy Ramos

When in November, minors between 2 and 18 years old complete their vaccination with the last dose of Soberana Plus, Cuba will be the first country in the world to resume face-to-face teaching with all its students vaccinated against COVID-19, said the Minister of Public Health of the island, José Ángel Portal Miranda.

In a press conference, offered this Tuesday in Havana, Portal Miranda confirmed that so far that age group, which represents 92% of the country's child population, has already received a dose of Sovereign 02.

Referring to the country's population, he said that as of October 10, 55.8% of Cuba’s inhabitants have already completed their immunization schedule, and 63.7% of those vaccinated have been immunized. These figures place Cuba as the country in the Americas with the highest percentage of vaccination and it is the nation with the highest daily vaccination rate in the world, highlighted Portal.

For his part, the president of the Group of Biotechnology and Pharmaceutical Industries (BioCubaFarma), Eduardo Martínez, referring to the pediatric population explained that soon the Center for Genetic Engineering and Biotechnology (CIGB) will deliver to the Center for State Control of Medicines, Equipment and Medical Devices (Cecmed), national regulatory authority, its report on studies in minors between the ages of two and 18 with this drug.

At this time, Martínez said, Cuba is evaluating doing an anti-COVID-19 clinical trial in children under two years of age, after the positive results of the Soberana and Abdala scheme in other studies and mass vaccination, due to the high safety proven in Cuban immunogens.

In another part of his speech, the president of BioCubaFarma referred to the production of Cuban vaccines, which will be increased as much as necessary to guarantee the dose of boosters to convalescents and other objectives. He also said the Cuban biopharmaceutical industry, in addition to the plants currently in production, plans to add others to make vaccines, such as the facility located in the Mariel Development Zone.

Regarding the commitments made with Vietnam, Venezuela and Nicaragua, he added the vaccines destined for these countries are in production for the remainder of the year and new agreements will be evaluated later. Regarding Iran, he said the authorities of that Middle East country recently reported on the excellent results obtained from the phase III trial of the Soberana 02 and Soberana Plus vaccines.